Alleviating oxidative stress in cancer immunotherapy: A role for histamine?

Medical Oncology

Volumn 17, Issue 4, 2000, Pages 258-269

  Hellstrand, K ^a   Brune, M ^a   Dahlgren, C ^a   Hansson, M ^a   Hermodsson, S ^a   Lindner P ^a   Mellqvist, U H ^a   Naredi, P ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

H istamine; IL 2; Immunotherapy; Leukemia; Macrophages; Melanoma; Monocytes; NK cells; T cells

Indexed keywords

ALPHA INTERFERON; CIMETIDINE; DIMAPRIT; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; INTERLEUKIN 2; RANITIDINE; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOTHERAPY; CELL PROTECTION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA; LYMPHOCYTE ACTIVATION; MACROPHAGE; MELANOMA; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033757501     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02782190     Document Type: Review

References (102)

1. Macrophage content of tumours in relation to metastatic spread and host immune reaction
2. The significance of macrophages in human and experimental tumors
3. Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies
4. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma
5. Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype
6. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression
7. Association of macrophages detected with monoclonal antibody 25 F 9 with progression and pathobiological classification of gastric carcinoma
8. Macrophages as regulators of immune responses against tumors
9. Tumor-induced immune dysfunction: The macrophage connection
10. Immunosuppression in human tumor-host interaction: Role of cytokines and alterations in signal-transducing molecules
11. Synergistic action of gamma interferon and catalase to reverse the suppressive effect of peritoneal macrophages on concanavalin A-induced lymphocyte proliferation
12. Catalase and lipopolysaccharide enhance proliferation in the rat mixed lymphocyte reaction
13. Histamine H2-receptor-mediated regulation of human natural killer cell activity
14. Role of serotonin in the regulation of human natural killer cell cytotoxicity
15. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2
16. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
17. Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex
18. Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses
19. Loss of T-cell receptor zeta chain and p561ck in T-cells infiltrating human renal cell carcinoma
20. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma
21. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: Correlation with the stage of the disease
22. Alterations in T cell receptor and signal transduction molecules in melanoma patients
23. Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer
24. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity
25. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy
26. Variable expression of CD3-zeta and associated protein tyrosine kinases in lymphocytes from patients with myeloid malignancies
27. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer
28. Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer
29. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells
30. Signaling defects in T lymphocytes of patients with malignancy
31. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites
32. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites
33. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma
34. Alterations in T cells of cancer-bearers: Whence specificity?
35. Biology of natural killer cells
36. Cell-to-cell mediated inhibition of natural killer cell proliferation by monocytes and its regulation by histamine H2-receptors
37. Histaminergic regulation of NK-cells: Protection against monocyte-induced apoptosis
38. Histamine protects T cells and Natural killer cells against oxidative stress
39. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma
40. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2
41. Signalling mechanisms and oxidative stress in apoptosis
42. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia
43. Histaminergic regulation of interferon-gamma (IFN-gamma) production by human natural killer (NK) cells
44. Suppressive Effects of Histamine on T Cell Activation
45. Histamine inhibits interferon-gamma production via suppression of interleukin 2 synthesis
46. Histamine acts directly on human T cells to inhibit interleukin-2 and interferon-gamma production
47. Inhibitory effects of histamine on interleukin 2 and gamma interferon production of different human T helper cell subsets
48. Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man
49. Passive local anaphylaxis: Demonstration of antitumor activity and complementation of intratumor BCG
50. Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: Influence of H1 and H2 histamine receptors
51. Inhibitory effects of tetragastrin and histamine on carcinogenesis in the small intestines of W rats by N-methyl-N-nitro-N-nitrosoguanidine
52. In vivo experimental demonstration that hyperhistaminism counteracts tumor growth
53. Inhibition of tumor growth induced by histamine in vivo and in vitro studies
54. Role of histamine in natural killer cell-mediated resistance against tumor cells
55. Effects of histamine, H1, H2 and Hic receptor antagonists and alpha-fluor-omethylhistidine on the growth of human colorectal cancer in the subrenal capsule assay
56. Effect of histamine dihydrochloride on tumor growth rate and tumor blood flow
57. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice
58. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth
59. Cimetidine protection against lethal tumor challenge in mice
60. Cimetidine reverses tumor growth enhancement of plasmacytoma tumors in mice demonstrating conditioned immunosuppression
61. Effects of cimetidine and indomethacin on the growth of dimethylhydrazine-induced or transplanted intestinal cancers in the rat
62. Effects of cimetidine, nitrite, cimetidine plus nitrite, and nitrosocimetidine on tumors in mice following transplacental plus chronic lifetime exposure
63. Phase II trial of cimetidine in metastatic melanoma. A Hoosier Oncology Group trial
64. Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma
65. A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer
66. Effect of cimetidine on survival after gastric cancer
67. Randomized controlled trial of an H2-receptor antagonist in gastric cancer
68. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells
69. Histamine in cancer immunotherapy
70. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation
71. Alterations of tumour cells, stroma and apoptosis in rat prostatic adenocarcinoma following treatment with histamine, interleukin-2 and irradiation
72. Histamine and Interleukin-2 inhibit growth and neovascularisation in malignant glioma
73. Histamine in immunotherapy of advanced melanoma: A pilot study
74. Prognostic factors in 1,521 melanoma patients with distant metastases
75. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells
76. Histamine and interleukin-2 in acute myelogenous leukemia
77. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis
78. Interleukin-2 therapy in relapsed acute myelogenous leukemia
79. Therapeutic strategies in metastatic renal cell carcinoma - An overview
80. Natural killer cells and tumor therapy
81. Immunohistochemical correlates of response to recombinant interleukin-2- based immunotherapy in humans
82. Clinical applications of IL-2
83. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy
84. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU
85. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN
86. Chemotherapy in combination with biomodulation: A 5-year experience with cyclophosphamide and interleukin-2
87. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment
88. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2
89. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients
90. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes
91. Fas ligand expression in primary colon adenocarcinomas: Evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
92. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10
93. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes
94. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance
95. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas
96. Fas ligand expression in thyroid carcinomas: A potential mechanism of immune evasion
97. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
98. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: A potential mechanism of apoptotic epithelial turnover
99. CD95 ligand expression as a mechanism of immune escape in breast cancer
100. Histamine, Cimetidine and colorectal cancer
101. Safety and feasibility of IL-2 plus histamine dihydrochloride (Maxamine (TM)) in AML patients in first or subsequent complete remission
102. Immunotherapy with IL-2 and histamine upregulates downmodulated T cell and NK cell-associated zeta expression in acute myeloid leukemia (AML)